EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 38 / Numéro 12 (Décembre 2022) Med Sci (Paris), 38 12 (2022) 1052-1060 Références
Open Access
Numéro
Med Sci (Paris)
Volume 38, Numéro 12, Décembre 2022
Un monde de virus
Page(s) 1052 - 1060
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2022168
Publié en ligne 13 décembre 2022
  1. Tangy F, Tournier JN. L’homme façonné par les virus. Paris : Édition Odile Jacob, 2021. [Google Scholar]
  2. Tournier JN, Tangy F. Les vaccins pour les nuls Paris: Édition First, 2017. [Google Scholar]
  3. Tangy F, Tournier JN. Le petit livre des vaccins. Paris : Édition First, 2022. [Google Scholar]
  4. Chaudhary N, Weissman D, Whitehead KA. mRNA Vaccines for Infectious Diseases: Principles, Delivery and Clinical Translation. Nat Rev Drug Discov 2021; 20 : 817–38. [CrossRef] [PubMed] [Google Scholar]
  5. Jackson NAC, Kester KE, Casimiro D, et al. The Promise of mRNA Vaccines: A Biotech and Industrial Perspective. NPJ Vaccines 2020; 5 : 11. [CrossRef] [PubMed] [Google Scholar]
  6. Pardi N, Hogan MJ, Porter FW et al. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov 2018 ; 17 : 261–279. [CrossRef] [PubMed] [Google Scholar]
  7. Meslé MM, Brown J, Mook P, et al. Estimated Number of Deaths Directly Averted in People 60 Years and Older as a Result of COVID-19 Vaccination in the WHO European Region, December 2020 to November 2021. Eurosurveillance 2021; 26 : 2101021. [Google Scholar]
  8. https://covid19.who.int. [Google Scholar]
  9. Roldão A, Mellado MCM, Castilho LR et al. Virus-like particles in vaccine development. Expert Rev Vaccines 2010 ; 9 : 1149–1176. [CrossRef] [PubMed] [Google Scholar]
  10. Rappuoli R, Bottomley MJ, D’Oro U et al. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med 2016 ; 213 : 469–481. [CrossRef] [PubMed] [Google Scholar]
  11. Dormitzer PR, Grandi G, Rappuoli R. Structural vaccinology starts to deliver. Nat Rev Microbiol 2012 ; 10 : 807–813. [CrossRef] [PubMed] [Google Scholar]
  12. Travieso T, Li J, Mahesh S, et al. The use of viral vectors in vaccine development. NPJ Vaccines 2022; 7 : 75. [CrossRef] [PubMed] [Google Scholar]
  13. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383 : 2603–15. [CrossRef] [PubMed] [Google Scholar]
  14. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med 2021; 385 : 2348–60. [CrossRef] [PubMed] [Google Scholar]
  15. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol 2010 ; 28 : 573–579. [CrossRef] [PubMed] [Google Scholar]
  16. Moratorio G, Henningsson R, Barbezange C et al. Attenuation of RNA viruses by redirecting their evolution in sequence space. Nat Microbiol 2017 ; 2 : 17088. [CrossRef] [PubMed] [Google Scholar]
  17. He F, Madhan S, Kwang J. Baculovirus vector as a delivery vehicle for influenza vaccines. Expert Rev Vaccines 2009 ; 8 : 455–467. [CrossRef] [PubMed] [Google Scholar]
  18. Maharjan PM, Choe S. Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines. Vaccines 2021; 9 : 992. [CrossRef] [PubMed] [Google Scholar]
  19. Robert-Guroff M.. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007 ; 18 : 546–556. [CrossRef] [PubMed] [Google Scholar]
  20. Prow NA, Jimenez Martinez R, Hayball JD et al. Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines. Expert Rev Vaccines 2018 ; 17 : 925–934. [CrossRef] [PubMed] [Google Scholar]
  21. Coughlan L, Kremer EJ, Shayakhmetov DM. Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens. Mol Ther 2022; 30 : 1822–49. [CrossRef] [PubMed] [Google Scholar]
  22. Frantz PN, Teeravechyan S, Tangy F. Measles-derived vaccines to prevent emerging viral diseases. Microbes Infect 2018 ; 20 : 493–500. [CrossRef] [PubMed] [Google Scholar]
  23. Monath TP, Seligman SJ, Robertson JS et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 2015 ; 33 : 62–72. [CrossRef] [PubMed] [Google Scholar]
  24. Henao-Restrepo AM, Camacho A, Longini IM et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit !). Lancet 2017 ; 389 : 505–518. [CrossRef] [PubMed] [Google Scholar]
  25. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol Rev 2022 Jun 22. DOI: 10.1111/imr.13089. [PubMed] [Google Scholar]
  26. https://www.cancer.org/research/cancer-facts-statistics/global.html. [Google Scholar]
  27. Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol 2022 Jul 12. DOI: 10.2217/fon-2022-0440. [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.